ALXN2220
Asset
Binds misfolded transthyretin and promotes immune-mediated clearance of cardiac amyloid deposits.
- Stage
- Phase 2
- Modality
- Antibody
- Target
- Proteostasis
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Amyloid transthyretin cardiomyopathy
Phase 2, Active not recruiting, NCT07213583, clinicaltrials.gov, 10 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials1
- Evidence for its targets2
- Competitors6
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.